CTX310 CRISPR Therapy Delivers 52.5% LDL and 47.8% Triglyceride Reductions at 12 Months in Phase I Trial

The Phase I dose-escalation study administered CTX310 at 0.1–0.8 mg/kg as a one-time intravenous infusion after corticosteroid and antihistamine pretreatment. Patients were followed for 12 months with serial lipid panels, liver enzymes, and off-target editing assessments. The highest dose cohort showed mean LDL reduction of 52.5% and triglyceride reduction of 47.8% from baseline, with ANGPTL3 protein levels suppressed correspondingly. Long-term monitoring is planned for 15 years per FDA gene-editing guidance.

These results extend the two-month data presented in 2025 and align with prior observational genetics linking loss-of-function ANGPTL3 variants to 41% lower coronary disease risk. Unlike PCSK9 inhibitors requiring repeated dosing, CTX310 offers potential one-time administration. However, the small sample and short duration limit conclusions about cardiovascular event reduction or rare off-target effects in diverse populations.

Larger Phase II trials must confirm durability beyond 12 months, assess atherosclerotic outcomes, and evaluate cost-effectiveness against existing therapies. Regulatory pathways for in vivo CRISPR will also require standardized long-term surveillance protocols.

This remains a Phase I study with 15 participants; it demonstrates biological activity and short-term safety but cannot yet establish clinical benefit or generalizability.